Morey L. Smith
AbbVie (United States)(US)
Publications by Year
Research Areas
Cell death mechanisms and regulation, Chronic Lymphocytic Leukemia Research, Bioactive Compounds and Antitumor Agents, Synthesis and Characterization of Heterocyclic Compounds, Signaling Pathways in Disease
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)(2015)427 cited
- → Bcl-2 family proteins are essential for platelet survival(2007)422 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC(2002)188 cited
- → Potential mechanisms of resistance to venetoclax and strategies to circumvent it(2017)186 cited
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208(2013)
- → Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity(2015)150 cited
- → The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo(2011)148 cited